Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica - PubMed
4 hours ago
- #secukinumab
- #polymyalgia rheumatica
- #clinical trial
- A Phase 3 trial evaluated secukinumab, an interleukin-17A inhibitor, in patients with relapsed polymyalgia rheumatica (PMR) over 52 weeks.
- Patients received either secukinumab 300 mg, secukinumab 150 mg, or placebo, all with a tapering prednisone regimen for 24 weeks.
- The primary outcome was sustained remission at week 52, achieved by 41.2% (SEC-300), 40.6% (SEC-150), and 20.4% (placebo), with secukinumab showing significant superiority over placebo (P<0.001).
- Secukinumab treatment resulted in lower mean cumulative glucocorticoid doses (1603.7 mg for SEC-300, 1683.2 mg for SEC-150) compared to placebo (2093.0 mg).
- Safety profiles were similar across groups, with serious adverse events occurring in 13.5-15.9% of secukinumab patients and 14.2% for placebo; nasopharyngitis and infections were more common with secukinumab.
- The study concludes that secukinumab plus glucocorticoid taper is more effective for sustained remission and reduces glucocorticoid exposure compared to taper alone in relapsed PMR patients.